Claudio Semeraro

The rise of disruptive therapies, including cell and gene therapies, personalized medicines, and biologics, is revolutionizing the pharmaceutical landscape. With an estimated 30% of new drugs in development classified as personalized or precision therapies, the need to adapt clinical trial supply chains to accommodate these innovations has never been more critical. However, adapting to this new paradigm is complex. Disruptive therapies often demand specialized handling, storage, and distribution, while production processes are intricate and require precise scaling. Regulatory frameworks for these novel treatments are still evolving, creating additional hurdles for trial planning. Moreover, the rise of decentralized trial models adds further logistical layers, complicating supply chain efficiency

Join this panel discussion as we discuss:

• Customizing Supply Chains for Advanced Therapies: Strategies for addressing the unique logistical needs of personalized and biologic therapies.
• Scalability Challenges: Balancing production demands with supply requirements for early phase trials.
• Cold Chain and Storage Solutions: Innovations in maintaining stability and integrity for sensitive materials.
• Integration of Decentralized Trials: Tackling the complexities of supply distribution in a decentralized trial environment.